DPP-4 inhibitors show no clear effect on diabetic eye disease risk
Last updated May 16, 2026
Key finding
DPP-4 inhibitors appear safe for diabetic eye disease, showing no increased risk.
This review looked at whether DPP-4 inhibitors, a type of diabetes pill, affect the risk of diabetic eye disease. Researchers analyzed seven studies involving people with type 2 diabetes from several countries. The results showed no clear difference in eye disease risk between people taking DPP-4 inhibitors and those on other diabetes medications. This finding was consistent across different groups, though individual study results varied.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Systematic Review
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
DPP-4 inhibitors appear safe for diabetic eye disease, showing no increased risk.
Published in
Journal Reference
Publication details and source links for this paper.
Wang M, Lu J, Dong J. Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies. BMC Ophthalmol. 2024;24:272. doi:10.1186/s12886-024-03535-1
Main Effects
New diabetic eye disease → → (no clear change)
Worsening existing eye disease → → (no clear change)
Evidence Suggest
- DPP-4 inhibitors do not appear to increase or decrease the risk of developing diabetic eye disease
- DPP-4 inhibitors show no clear effect on worsening of existing eye disease
- Results were similar across different countries, though individual studies showed some variation
Who this applies to
Adults with type 2 diabetes taking oral medications, especially those considering DPP-4 inhibitors
Keep in Mind
These were routine care studies, not controlled trials, so other differences between groups could affect results
Between the Lines
- Eye disease identified through records, not comprehensive exams
- Short follow-up in most studies (2-3 years)
- Results varied widely between studies
- Observational design limits certainty about cause and effect
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.